Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oku, A.
Right arrow Articles by Endou, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oku, A.
Right arrow Articles by Endou, H.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 48, Issue 9 1794-1800, Copyright © 1999 by American Diabetes Association

ARTICLES

T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes

A Oku, K Ueta, K Arakawa, T Ishihara, M Nawano, Y Kuronuma, M Matsumoto, A Saito, K Tsujihara, M Anai, T Asano, Y Kanai and H Endou
Discovery Research Laboratory, Tanabe Seiyaku Company Ltd., Saitama, Toda, Japan.

T-1095A and T-1095 are synthetic agents derived from phlorizin, a specific inhibitor of Na+-glucose cotransporters (SGLTs). Unlike phlorizin, T-1095 is absorbed into the circulation via oral administration, is metabolized to the active form, T-1095A, and suppresses the activity of SGLTs in the kidney. Orally administered T-1095 increases urinary glucose excretion in diabetic animals, thereby decreasing blood glucose levels. Indeed, the postprandial hyperglycemia after a meal load was shown to be suppressed by this compound in streptozotocin (STZ)-induced diabetic rats. With long-term T-1095 treatment, both blood glucose and HbA1c levels were reduced in STZ-induced diabetic rats and yellow KK mice. In addition, there was amelioration of abnormal carbohydrate metabolism, i.e., hyperinsulinemia and hypertriglyceridemia, and of the development of microalbuminuria, in yellow KK mice. Thus, T-1095 may be a useful antidiabetic drug, providing a novel therapeutic approach for diabetes.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
S. Han, D. L. Hagan, J. R. Taylor, L. Xin, W. Meng, S. A. Biller, J. R. Wetterau, W. N. Washburn, and J. M. Whaley
Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats
Diabetes, June 1, 2008; 57(6): 1723 - 1729.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. M. Li, C. T. Che, C. B. S. Lau, P. S. Leung, and C. H. K. Cheng
Desoxyrhaponticin (3,5-Dihydroxy-4'-methoxystilbene 3-O-beta-D-glucoside) Inhibits Glucose Uptake in the Intestine and Kidney: In Vitro and in Vivo Studies
J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 38 - 46.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. Katsuno, Y. Fujimori, Y. Takemura, M. Hiratochi, F. Itoh, Y. Komatsu, H. Fujikura, and M. Isaji
Sergliflozin, a Novel Selective Inhibitor of Low-Affinity Sodium Glucose Cotransporter (SGLT2), Validates the Critical Role of SGLT2 in Renal Glucose Reabsorption and Modulates Plasma Glucose Level
J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 323 - 330.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
H. Rahmoune, P. W. Thompson, J. M. Ward, C. D. Smith, G. Hong, and J. Brown
Glucose Transporters in Human Renal Proximal Tubular Cells Isolated From the Urine of Patients With Non-Insulin-Dependent Diabetes
Diabetes, December 1, 2005; 54(12): 3427 - 3434.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
C. Lajoie, A. Calderone, F. Trudeau, N. Lavoie, G. Massicotte, S. Gagnon, and L. Beliveau
Exercise training attenuated the PKB and GSK-3 dephosphorylation in the myocardium of ZDF rats
J Appl Physiol, May 1, 2004; 96(5): 1606 - 1612.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. Oku, M. Nawano, K. Ueta, T. Fujita, I. Umebayashi, K. Arakawa, T. Kano-Ishihara, A. Saito, M. Anai, M. Funaki, et al.
Inhibitory effect of hyperglycemia on insulin-induced Akt/protein kinase B activation in skeletal muscle
Am J Physiol Endocrinol Metab, May 1, 2001; 280(5): E816 - E824.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. Nawano, A. Oku, K. Ueta, I. Umebayashi, T. Ishirahara, K. Arakawa, A. Saito, M. Anai, M. Kikuchi, and T. Asano
Hyperglycemia contributes insulin resistance in hepatic and adipose tissue but not skeletal muscle of ZDF rats
Am J Physiol Endocrinol Metab, March 1, 2000; 278(3): E535 - E543.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Korn, T. Kuhlkamp, C. Track, I. Schatz, K. Baumgarten, V. Gorboulev, and H. Koepsell
The Plasma Membrane-associated Protein RS1 Decreases Transcription of the Transporter SGLT1 in Confluent LLC-PK1 Cells
J. Biol. Chem., November 21, 2001; 276(48): 45330 - 45340.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1999 by the American Diabetes Association.